Neuronetics (FRA:NRC) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:NRC Neuronetics Inc FRA:NRC
51 GF Score
Price €1.06
GF Value €1.52
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Neuronetics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Neuronetics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:NRC vs ZOMDF, RPID, OM: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Neuronetics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuronetics Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neuronetics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Neuronetics's Margin of Safety % (DCF Earnings Based) falls into.


FRA:NRC
51GF Score
Neuronetics Inc FRA:NRC
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuronetics (FRA:NRC) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued. The current stock price of €1.06 is trading 30.6% below its estimated GF Value™ of €1.52. GuruFocus considers Neuronetics to be Possible Value Trap.

Key valuation signals for FRA:NRC:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €1.52 vs. price of €1.06 (30.6% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuronetics Business Description

Other Exchanges STIM:USA
Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
51GF Score

Get the complete analysis for FRA:NRC

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.06
Price
€1.52
GF Value